Mylan acquires exclusive license to commercialise biosimilar to Humira

Morphotek Licenses Proprietary Eribulin-Linker Payload to Bliss Biopharmaceutical for Development of Therapeutic ADC

Promethera Biosciences purchases Baliopharm

Protalex Expands Phase 1/2 Study of PRTX-100 in Immune Thrombocytopenia to UK

SMC approves four new therapies for NHS Scotland

EMA Grants Orphan Drug Designation to Sancilio's Altemia for Treatment of Pediatric Patients with Sickle Cell Disease

On Target Laboratories treats first ovarian cancer patient under Pivotal Phase 3 OTL38 trial

Mark J. Alles Assumes Responsibilities of Departing Celgene President and COO

FDA Grants Orphan Drug Designation to PharmAbcine's TTAC-0001 for Glioblastoma Multiforme

ThromboGenics reveals initial data from THR-317 study

Amgen Receives FDA Approval of Blincyto for Treatment of MRD-Positive B-Cell Precursor ALL in Adults and Children

MediciNova's liver disease drug meets primary endpoint in phase 2 clinical trial

Regeneron submits DUPIXENT (dupilumab) for EMA review for treating inadequately controlled moderate-to-severe asthma

bluebird bio and Celgene Partner to Develop and Promote Anti-BCMA CAR T Cell Therapy in the US

Survey Shows Nearly 50% of Physicians Disapprove of Federal Government's Response to Opioid Crisis